Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.
| Revenue (TTM) | $1.51B |
| Gross Profit (TTM) | $972.95M |
| EBITDA | $-200.07M |
| Operating Margin | -13.80% |
| Return on Equity | -37.60% |
| Return on Assets | -7.36% |
| Revenue/Share (TTM) | $8.40 |
| Book Value | $2.75 |
| Price-to-Book | 25.67 |
| Price-to-Sales (TTM) | 9.19 |
| EV/Revenue | 9.04 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 23.10% |
| Shares Outstanding | $177.36M |
| Float | $125.56M |
| % Insiders | 36.15% |
| % Institutions | 58.92% |
Volatility is currently expanding
Tempus AI delivered robust Q3 results, with 23% YoY revenue growth and an inflection after four quarters of deceleration. Diagnostics volumes surged, notably MRD tests up 300% YoY, while Data & Applications revenue accelerated to 33% growth. Major partnerships with Bristol Myers Squibb, Moderna, and Merck validate TEM's strategic positioning in AI-driven medicine.
Tempus AI NASDAQ: TEM is among the more volatile AI-related stocks, trading in a wide range and testing upper limits several times since its IPO. Volatility stems from several factors, including the path to profitability, cash burn, and immense opportunity.
Tempus AI raises its 2026 revenue outlook as oncology demand, expanding data partnerships and reimbursement-driven pricing gains fuel growth prospects for 2027.
Baron SMID Cap ETF returned -2.87% (NAV) in the third quarter, outperforming its benchmark, the Russell 2500 Growth Index, which returned -10.35%. Top contributors were Rubrik, Inc., Tempus AI, Inc., and Netskope, Inc. Top detractors were Axon Enterprise, Inc., Forgent Power Solutions, Inc., and Mercury Systems, Inc.
The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.
Tempus AI (NASDAQ:TEM | TEM Price Prediction) was trading higher this afternoon. It sat at $80.31, up 11.21% after the precision medicine company reported third-quarter results before the open.
Tempus AI, Inc. (TEM) Q3 2026 Earnings Call Transcript
The headline numbers for Tempus (TEM) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tempus AI (TEM) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.11 per share a year ago.
Tempus AI NASDAQ: TEM reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive results. The company also raised its full-year revenue outlook and said it generated positive adjusted EBITDA during the quarter.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TEM and any ticker you trade — then tracks every position and per-strategy win rate.
